This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix submits supplemental NDA for Dextenza

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A supplemental new drug application for Dextenza has been submitted to the FDA to expand its indication to include the treatment of ocular inflammation after ophthalmic surgery, Ocular Therapeutix announced in a press release.

Dextenza (dexamethasone ophthalmic insert) was approved by the FDA in November 2018 and is currently indicated for postsurgical ocular pain.

“Submission of this sNDA on the heels of the initial Dextenza approval is another significant milestone for Ocular Therapeutix. The potential market opportunity for postoperative ocular pain and inflammation is substantial, and there remains an important unmet need to address the issue of noncompliance given currently available treatment options,” Antony Mattessich, Ocular Therapeutix president and CEO, said in the release.

In addition, Ocular Therapeutix has submitted an application to CMS for transitional pass-through payment status and an application for a J-code for Dextenza, the release said.